Please login to the form below

Not currently logged in
Email:
Password:

Aradigm

This page shows the latest Aradigm news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

Aradigm has been unable to convince an FDA advisory committee that that its inhaled version of ciprofloxacin should be approved for chronic infections in patients with a serious lung disease. ... It paid Aradigm a $5m milestone last September after the

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    The companies have already succeeded where ill-fated programmes from Lilly/Alkermes and Novo Nordisk/Aradigm failed, but it must now prove it can do better than Pfizer's Exubera, launched

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols . ... Licence equity. Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics